Skip to main content

Table 5 Response in ascites

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

Groups

N

Disappeared

(N) (%)

Decreased

(N) (%)

No change

(N) (%)

Increased

(N) (%)

NE

(N) (%)

P value*

All patients with ascites

40

3 (7.5)

11 (27.5)

12 (30)

12 (30)

2 (5)

0.88

Small to moderate ascites

26

3 (12)

6 (23)

9 (35)

8 (31)

0

 

Massive ascites

14

0

5 (36)

3 (21)

4 (29)

2 (14)

 
  1. Disappeard: disappearance of ascites
  2. Decreased: from moderate to small, from massive to moderate or small
  3. Increased: from small to moderate or massive, from moderate to massive
  4. *Comparison of response between 2 groups
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us